MRK.BA - Merck & Co., Inc.

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
100.00
0.00 (0.00%)
At close: 12:28PM ART
Stock chart is not supported by your current browser
Previous Close100.00
Open100.00
Bid0.00 x 0
Ask120.00 x 0
Day's Range100.00 - 100.00
52 Week Range100.00 - 111.65
Volume400
Avg. Volume279
Market Cap2.641T
BetaN/A
PE Ratio (TTM)96.81
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Better Buy: Johnson & Johnson vs. Merck
    Motley Fool4 hours ago

    Better Buy: Johnson & Johnson vs. Merck

    J&J stock is up in 2017, while Merck is down. But could the roles be reversed in 2018 and beyond?

  • Merck's Keytruda Misses Primary End Point for Gastric Cancer
    Zacksyesterday

    Merck's Keytruda Misses Primary End Point for Gastric Cancer

    Merck's (MRK) anti-PD-1 therapy Keytruda misses the primary endpoint in a phase III study, which analyzed it as a second-line treatment for patients with advanced gastric adenocarcinoma.

  • Reuters2 days ago

    Merck's Keytruda fails pivotal gastric cancer trial

    Merck & Co Inc said on Thursday a key late-stage trial testing its blockbuster drug, Keytruda, failed to meet its main goal of extending lives of patients with a type of gastric cancer. The trial, which was testing the drug as a second-line treatment, also failed to prevent the cancer from progressing in patients whose tumors expressed the PD-LI protein, the company said. The U.S. regulator earlier this year approved Keytruda as a third-line treatment for gastric cancer patients, who showed no response to two or more prior lines of therapy.

  • Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma
    Zacks4 days ago

    Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma

    Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.

  • Reuters5 days ago

    Merck raises stakes in lung cancer as rivals close in

    Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10 percent since the drugmaker several weeks ago said it would make survival a main goal of a key lung cancer trial for immunotherapy Keytruda, extending the study by up to a year. In the meantime, Roche Holding AG has shaken up Wall Street expectations for the $15-billion (£11.3 billion) lung cancer market, showing its Tecentriq immunotherapy slows the spread of advanced lung cancer when combined with older treatments.

  • Reuters5 days ago

    Roche: Tecentriq cocktail slows kidney cancer progression

    Combining Roche's Tecentriq immunotherapy with its older drug Avastin for the initial treatment of advanced kidney cancer reduced the risk of the disease worsening or of death in certain patients, the Swiss drugmaker said on Monday. The trial tested the combination against the current standard of care, Pfizer's Sutent, in patients with inoperable, locally advanced or metastatic renal cell carcinoma.

  • Reuters6 days ago

    Roche: Tecentriq cocktail slows kidney cancer progression

    Tecentriq, whose sales pale compared to established immunotherapies from Bristol-Myers Squibb and Merck & Co Inc, is a pillar of Roche's plan to replace revenue from its $20 billion-per-year trio of Avastin, Herceptin and Rituxan whose expiring patents have exposed them to cheaper competition. As a consequence, Roche is seeking to expand indications and patients eligible for treatment with its drug, which analysts see topping $4.6 billion in annual sales by 2023.

  • Merck & Co Inc (MRK): What You Have To Know Before Buying For The Upcoming Dividend
    Simply Wall St.7 days ago

    Merck & Co Inc (MRK): What You Have To Know Before Buying For The Upcoming Dividend

    Important news for shareholders and potential investors in Merck & Co Inc (NYSE:MRK): The dividend payment of $0.48 per share will be distributed into shareholder on 08 January 2018, andRead More...

  • GuruFocus.com9 days ago

    52-Week Company Lows

    Details the 52-week lows of the following companies: General Electric, Merck & Co, Schlumberger, Enterprise Products Partners, Kinder Morgan and Edison International

  • Why 2017 Was a Year to Forget for Merck & Co. Inc.
    Motley Fool9 days ago

    Why 2017 Was a Year to Forget for Merck & Co. Inc.

    Everything looked OK for the drugmaker until Merck delivered an unwelcome October surprise.

  • Reuters10 days ago

    Roche to seize leap-frog opportunity in lung cancer

    After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer. "We have a real chance to be at the forefront here," Chief Executive Severin Schwan said on Wednesday.

  • Top Analyst Reports for Home Depot, Boeing & Merck
    Zacks11 days ago

    Top Analyst Reports for Home Depot, Boeing & Merck

    Top Analyst Reports for Home Depot, Boeing & Merck

  • Investopedia11 days ago

    Biotech Stocks May See a New M&A Wave in 2018

    Struggling biotech giants could bolster their stocks in 2018 if they acquire smaller drug companies.

  • Market Realist11 days ago

    Analyst Recommendations for Merck & Co. in November 2017

    Wall Street analysts estimate Merck & Co.’s (MRK) top line to rise 1.1% to ~$40.2 billion in 2017. EPS (earnings per share) is expected to be $3.94 for 2017.

  • 3 Stocks That Cut Bigger Checks Than PepsiCo
    Motley Fool11 days ago

    3 Stocks That Cut Bigger Checks Than PepsiCo

    Pepsi is a fantastic business with a healthy dividend. But your quarterly check will be even larger if you invest in these three companies.

  • Market Realist11 days ago

    Analysts’ Estimates for Merck & Co. after 3Q17

    Wall Street analysts estimate that Merck will report EPS of $3.94 in 2017 compared to $3.78 in 2016.

  • Market Realist12 days ago

    Merck & Co.’s Animal Health Segment in 3Q17

    Merck & Co.'s (MRK) Animal Health segment reported revenues of $1 billion in 3Q17, a 16% rise compared to $865 million in 3Q16.

  • Market Realist12 days ago

    Merck’s Immunology and Cardiovascular Franchise in 3Q17

    In 3Q17, Merck's Remicade revenues fell ~31% to $214 million compared to $311 million in 3Q16. The fall was driven by lower sales due to generic competition and biosimilars.

  • Market Realist12 days ago

    GlaxoSmithKline’s Valuation in November 2017

    In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.

  • Market Realist12 days ago

    Merck’s Diabetes Portfolio in 3Q17

    The combined revenues of Merck's (MRK) Januvia and Janumet in 3Q17 was $1.52 billion, a 2% decline compared to $1.55 billion in 3Q16, mainly due to lower sales of Janumet.

  • Nestle, Stada prepare rival bids for Germany's Merck consumer health - sources
    Reuters15 days ago

    Nestle, Stada prepare rival bids for Germany's Merck consumer health - sources

    LONDON/FRANKFURT (Reuters) - Swiss food giant Nestle (NESN.S) and the private equity owners of German drug firm Stada (STAGn.DE) are both preparing tentative bids for Merck KgaA's (MRCG.DE) consumer health unit, several sources told Reuters. Merck's financial adviser JPMorgan has invited bids for the business, which is valued at about 4 billion euros (£3.5 billion), ahead of a Dec. 15 deadline, the sources said. Nestle is widely seen as a natural buyer for the maker of Seven Seas vitamins and Bion nutritional supplements, after previous talks to set up a consumer joint venture with Merck fell through over the summer.

  • Market Realist15 days ago

    Merck’s Gardasil and Other Human Vaccines in 3Q17

    Merck & Co.'s (MRK) Gardasil franchise reported total sales of $675 million in3Q17, a 22% fall compared to $860 million in 3Q16.